| Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study B Schurch, M de SÈZE, P Denys, E Chartier-Kastler, F Haab, K Everaert, ... The Journal of urology 174 (1), 196-200, 2005 | 700 | 2005 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study D Lobo, JM Devys Anaesthesia 77 (1), 110, 2021 | 584* | 2021 |
| European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity A Reitz, M Stöhrer, G Kramer, G Del Popolo, E Chartier-Kastler, J Pannek, ... European urology 45 (4), 510-515, 2004 | 532 | 2004 |
| Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review G Karsenty, P Denys, G Amarenco, M De Seze, X Gamé, F Haab, ... European urology 53 (2), 275-287, 2008 | 350 | 2008 |
| Urinary incontinence in French women: prevalence, risk factors, and impact on quality of life A Lasserre, C Pelat, V Guéroult, T Hanslik, E Chartier-Kastler, T Blanchon, ... European urology 56 (1), 177-183, 2009 | 293 | 2009 |
| Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm M Peycelon, V Hupertan, E Comperat, R Renard-Penna, C Vaessen, ... The Journal of urology 181 (1), 35-41, 2009 | 250 | 2009 |
| Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia EJ Chartier-Kastler, JLHR Bosch, M Perrigot, MB CHANCELLOR, ... The Journal of urology 164 (5), 1476-1480, 2000 | 232 | 2000 |
| Sacral neuromodulation: standardized electrode placement technique KE Matzel, E Chartier‐Kastler, CH Knowles, PA Lehur, A Muñoz‐Duyos, ... Neuromodulation: Technology at the Neural Interface 20 (8), 816-824, 2017 | 209 | 2017 |
| Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum … E Compérat, A Reitz, A Delcourt, F Capron, P Denys, E Chartier-Kastler European urology 50 (5), 1058-1064, 2006 | 204 | 2006 |
| International Continence Society best practice statement for use of sacral neuromodulation HB Goldman, JC Lloyd, KL Noblett, MP Carey, JC Castaño Botero, ... Neurourology and urodynamics 37 (5), 1823-1848, 2018 | 203 | 2018 |
| Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus … M Oelke, K Becher, D Castro-Diaz, E Chartier-Kastler, M Kirby, A Wagg, ... Age and ageing 44 (5), 745-755, 2015 | 182 | 2015 |
| Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo … P Denys, L Le Normand, I Ghout, P Costa, E Chartier-Kastler, P Grise, ... European urology 61 (3), 520-529, 2012 | 169 | 2012 |
| Focused extracorporeal pyrotherapy G Vallancien, E Chartier-Kastler, N Bataille, D Chopin, M Harouni, ... European urology 23 (Suppl. 1), 48-52, 1993 | 168* | 1993 |
| Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma M Rouprêt, V Hupertan, O Traxer, G Loison, E Chartier-Kastler, P Conort, ... Urology 67 (6), 1181-1187, 2006 | 163 | 2006 |
| Management of neurogenic bladder in patients with multiple sclerosis V Phé, E Chartier–Kastler, JN Panicker Nature Reviews Urology 13 (5), 275-288, 2016 | 161 | 2016 |
| Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE B Monz, E Chartier-Kastler, C Hampel, G Samsioe, S Hunskaar, ... European urology 51 (4), 1073-1082, 2007 | 161 | 2007 |
| Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up—an … J Salomon, P Denys, C Merle, E Chartier-Kastler, C Perronne, JL Gaillard, ... Journal of Antimicrobial Chemotherapy 57 (4), 784-788, 2006 | 149 | 2006 |
| Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection M Rouprêt, O Traxer, M Tligui, P Conort, E Chartier-Kastler, F Richard, ... European urology 51 (3), 709-714, 2007 | 148 | 2007 |
| Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions MB Chancellor, EJ Chartier-Kastler Neuromodulation: Technology at the Neural Interface 3 (1), 15-26, 2000 | 142 | 2000 |
| High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology X Rebillard, M Soulié, E Chartier‐Kastler, JL Davin, JP Mignard, ... BJU international 101 (10), 1205-1213, 2008 | 139 | 2008 |
DENYS PierreProfesseur de Médecine, Hopital Raymond Poincaré, Université de VersaillesВерификована је имејл адреса на aphp.fr